Get the Stockscreener App
8.49
0.59%
-0.05
Zevra Therapeutics Inc stock is traded at $8.49, with a volume of 2.33M.
It is down -0.59% in the last 24 hours and down -5.35% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$8.54
Open:
$8.43
24h Volume:
2.33M
Relative Volume:
2.79
Market Cap:
$453.16M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-9.0319
EPS:
-0.94
Net Cash Flow:
$-33.83M
1W Performance:
+0.12%
1M Performance:
-5.35%
6M Performance:
+94.72%
1Y Performance:
+78.93%
1-Day Range:
$8.343
$8.83
1-Week Range:
$8.17
$8.83
52-Week Range:
$4.20
$9.76
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.49 | 453.16M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
(ZVRA) Investment Analysis and Advice - Stock Traders Daily
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - The Manila Times
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year - StockTitan
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Fmr LLC Acquires 2,312,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Restructures to Focus on Rare Diseases - MSN
A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - PharmaVoice
Zevra Therapeutics, Inc. Announces Departure of Executives - Marketscreener.com
Zevra Therapeutics Announces Organizational Changes - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus Price Target from Brokerages - MarketBeat
Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan
Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease - Yahoo Finance
What is HC Wainwright’s Forecast for ZVRA FY2024 Earnings? - Defense World
ZVRA stock touches 52-week high at $9.6 amid robust growth - Investing.com UK
Equities Analysts Set Expectations for ZVRA FY2024 Earnings - MarketBeat
Zevra launches first FDA-approved NPC treatment By Investing.com - Investing.com Australia
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C - The Manila Times
Zevra launches first FDA-approved NPC treatment - Investing.com India
HC Wainwright Has Negative Forecast for ZVRA FY2028 Earnings - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Guggenheim Initiates Coverage of Zevra Therapeutics (ZVRA) with Buy Recommendation - MSN
Zevra Therapeutics (STU:1GDA) Enterprise Value : €424.12 Mil (As of Nov. 20, 2024) - GuruFocus.com
Zevra Therapeutics Q3 2024 Earnings Preview - MSN
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
Cantor Fitzgerald Issues Negative Estimate for ZVRA Earnings - MarketBeat
What is William Blair's Forecast for ZVRA FY2024 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report - Yahoo Finance
Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study - Ehlers-Danlos News
Simplify Asset Management Inc. Invests $833,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
What is William Blair's Estimate for ZVRA FY2026 Earnings? - MarketBeat
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results - Simply Wall St
Roth Capital Forecasts Lower Earnings for Zevra Therapeutics - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Decline in Short Interest - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zevra Therapeutics reports Q3 financial results - Investing.com
Canaccord Genuity Group Issues Pessimistic Forecast for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price - MarketBeat
Q4 Earnings Forecast for ZVRA Issued By Roth Capital - MarketBeat
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Woodline Partners LP's Strategic Acquisition of Zevra Therapeuti - GuruFocus.com
Janney Montgomery Scott LLC Sells 127,755 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Zevra Therapeutics’ Transformative Third Quarter 2024 - TipRanks
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zevra Therapeutics Inc Stock (ZVRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
| Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
| Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):